Peter Mohrer, MD
Psychiatry · Guilford, CTNPI 1205800463
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,955 of the $38,054 with a category attached, or 86.6%. AbbVie accounts for 86.3% of it on its own, with 14 other manufacturers making up the rest. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $190.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- Corium, LLC$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$858
- Johnson & Johnson$589
- Otsuka America Pharmaceutical, Inc.$285
- Sunovion Pharmaceuticals Inc.$146
- plus $683 from 9 others
What the payments were for
- Consulting fees$3601%
- Speaking & faculty fees$32,95587%
- Food & beverage$4,67812%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 107 | $32,846 |
| Corium, LLC | 45 | $2,648 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $858 |
| Johnson & Johnson | 11 | $589 |
| Otsuka America Pharmaceutical, Inc. | 5 | $285 |
| Sunovion Pharmaceuticals Inc. | 3 | $146 |
| Vanda Pharmaceuticals Inc. | 2 | $137 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 3 | $112 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Alkermes, Inc. | 3 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $46 |
| TMS Neurohealth Centers Inc. | 1 | $35 |
| Lundbeck LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,054 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 26 | $52,028 |
| TrintellixVortioxetine Hydrobromide | 53 | $43,200 |
| RexultiBrexpiprazole | 20 | $37,201 |
| VyvanseLisdexamfetamine Dimesylate | 34 | $12,753 |
| Bupropion XlBupropion Hcl | 173 | $5,055 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 43 | $4,106 |
| Gabapentin | 194 | $3,296 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 114 | $3,289 |
| Ziprasidone Hcl | 18 | $3,091 |
| Methylphenidate Hcl | 93 | $3,002 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 103 | $2,736 |
| Mirtazapine | 102 | $2,299 |
| Olanzapine | 90 | $2,233 |
| Quetiapine Fumarate | 124 | $2,214 |
| Duloxetine Hcl | 114 | $2,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $57 | $55,95387 claims |
| AbbVieVraylar | $32,846 | $52,02826 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $285 | $37,20120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Guilford
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
- David MatuskeyFarmington$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.